Mayo v. Prometheus - The United States Supreme Court has done it again

by Ladas & Parry LLP
Contact

In Bilski v. Kappos, the Court reiterated that abstract ideas are not patent eligible, gave little guidance as to what it meant by “abstract idea” other than that the Court was concerned about claims that were too broad and referred us to its prior decisions, especially Diamond v. Diehr for guidance.

In its latest case on patent eligibility, Mayo Collaborative Services v. Prometheus Laboratories the Court reiterated that laws of nature are not patent eligible, gave little guidance as to what it meant by “law of nature” other than that the Court was concerned about claims that were too broad and referred us to its prior decisions, especially Diamond v. Diehr again for guidance.

A typical claim (claim 1 of US 6,355,623) in Prometheus’s patent reads:

1. A method of optimizing therapeutic efficacy for treatment of an immune-mediated gastrointestinal disorder, comprising:

(a) administering a drug providing 6-thioguanine to a subject having said immune-mediated gastrointestinal disorder; and

(b) determining the level of 6-thioguanine in said subject having said immune-mediated gastrointestinal disorder,

wherein the level of 6-thioguanine less than about 230 pmol per 8 x108 red blood cells indicates a need to increase the amount of said drug subsequently administered to said subject and

wherein the level of 6-thioguanine greater than about 400 pmol per 8.x 108 red blood cells indicates a need to decrease the amount of said drug subsequently administered to said subject.

The Supreme Court in a unanimous opinion written by Justice Breyer saw the claim as comprising a law of nature in the form of “relationships between concentrations of certain metabolites in the blood and the likelihood that a dosage of thiopurine drug will prove ineffective or cause harm”. The other elements of the claim were regarded as “routine conventional activity already engaged in by the scientific community and these steps when viewed as a whole add nothing significant beyond the sum of their parts taken separately”.

Breyer J noted:

If a law of nature is not patentable, then neither is a process reciting a law of nature, unless that process has additional features that provide practical assurance that the process is more than a drafting effort designed to monopolize the law of nature itself. A patent, for example, could not simply recite a law of nature and then add the instruction “apply the law.”

Breyer J distinguished the present case from Diamond v. Diehr (a case where the Supreme Court had held that use of the Arrhenius equation to control a method for curing rubber was patentable even though the Arrehenius equation itself was not) as follows:

The Court pointed out that the basic mathematical equation, like a law of nature, was not patentable. But it found the overall process patent eligible because of the way the additional steps of the process integrated the equation into the process as a whole. Those steps included“installing rubber in a press, closing the mold, constantly determining the temperature of the mold, constantly re-calculating the appropriate cure time through the use of the formula and a digital computer, and automatically opening the press at the proper time.” It nowhere suggested that all these steps, or at least the combination of those steps, were in context obvious, already in use, or purely conventional.

This is true. In Diehr, the Court never commented on whether the extra steps were obvious or not. What it did say was

In determining the eligibility of respondents’ claimed process for patent protection under§101, their claims must be considered as a whole. It is inappropriate to dissect claims into old and new elements and then ignore the presence of the old elements in the analysis.

The Court has, however, been consistent in holding that “insignificant post-solution activity will not transform an unpatentable principle (or law of nature) into a patentable process”.

The Mayo decision therefore poses two problems: 1) what is a law of nature and 2) if a method utilizes a law of nature when does insignificant post solution activity become patent eligibility-creating non-conventional activity.

Having regard to the first point, reading the term “law of nature” as broadly as Breyer J. did in the present case, seems to lead to the conclusion that almost all method inventions (apart from business methods which have their own problems) fall within the definition. It is natural for chemicals to react when put together. It is natural for electrons to flow through a conductor. What Breyer J.’s opinion fails to recognize is that it is not natural to choose which chemicals to react or through what particular conductors electrons should be caused to flow, or dare one say it, what particular metabolites to monitor when seeking to adjust dosages of thipurines to give to a patient.

Under the Breyer analysis, this question of selection will apparently have to be addressed when considering whether other steps set out in a claim are conventional or not. At first glance, it would seem that Breyer J.’s opinion leaves little room for this. However, apparently realizing the problems that a broad interpretation of the decision would cause, he goes on to state:

We need not, and do not, now decide whether were the steps at issue here less conventional, these features of the claims would prove sufficient to invalidate them. For here, as we have said, the steps add nothing of significance to the natural laws themselves. Unlike, say, a typical patent on a new drug or a new way of using an existing drug, the patent claims do not confine their reach to particular applications of those laws.

So, had the claim been written as a method of treating an immune-mediated gastrointestinal disorder with a thiopurine and adjusting the dose in accordance with the results of a determination of 6-thioguanine levels in the blood, would the Supreme Court have come to a different conclusion? Who can say? But it is probably worth a try. Otherwise, there would seem to be a problem in securing patent protection for new methods of diagnosis.

What the Supreme Court has made clear, however, both in Bilski and Mayo is its concern that broad patent claims may impeded future research. The issue is not new. Section 2 of the 1793 Act specifically dealt with it by pointing out that the inventor of an improvement patent could not use that improvement without the consent of the owner of the dominant patent. The issue is, however, one that keeps on coming up. Indeed the Federal Circuit’s approach to written description and the need for the specification to show “possession” of the invention as set out in Ariad Pharmaceuticals, Inc et. al v. Eli Lilly and Co. can be seen as an example of the same concern. In Mayo, Breyer J. expresses the concern as follows:

there is a danger that the grant of patents that tie up their use will inhibit future innovation premised upon them, a danger that becomes acute when a patented process amounts to no more than an instruction to “apply the natural law,” or otherwise forecloses more future invention than the underlying discovery could reasonably justify.

This is a slippery slope. How does one determine what is “reasonably justified”? In England, Lord Hoffman adopted this approach in the House of Lord’s decision 1997 in Biogen v. Medeva. Ten years later he deliberately stepped down to the Court of Appeal to deliver the judgment in Lundbeck v. Generics to explain that this approach was not universally applicable.

If there is one conclusion that can be drawn from Bilski and Mayo, however, it is that the Supreme Court dislikes broad claims and not receiving any suitable cases under 35 USC 112 on which to express this, has taken the opportunity of cases under 35 USC 101 to do so. This is unfortunate since deciding a policy issue on the basis of an inappropriate part of the statute almost invariably leads to unforeseen consequences.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Ladas & Parry LLP | Attorney Advertising

Written by:

Ladas & Parry LLP
Contact
more
less

Ladas & Parry LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.